The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Prostaglandin I2 Market Research Report 2024
Synopsis
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
Global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostaglandin I2 market research.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segment by Application
For Injection
For Oral
For Inhalation
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostaglandin I2 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
Global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostaglandin I2 market research.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segment by Application
For Injection
For Oral
For Inhalation
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostaglandin I2 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Prostaglandin I2 Market Overview
1.1 Product Overview and Scope of Prostaglandin I2
1.2 Prostaglandin I2 Segment by Type
1.2.1 Global Prostaglandin I2 Market Value Comparison by Type (2023-2029)
1.2.2 Epoprostenol Sodium
1.2.3 Treprostinil
1.2.4 Iloprost
1.2.5 Beraprost Sodium
1.3 Prostaglandin I2 Segment by Application
1.3.1 Global Prostaglandin I2 Market Value by Application: (2023-2029)
1.3.2 For Injection
1.3.3 For Oral
1.3.4 For Inhalation
1.4 Global Prostaglandin I2 Market Size Estimates and Forecasts
1.4.1 Global Prostaglandin I2 Revenue 2018-2029
1.4.2 Global Prostaglandin I2 Sales 2018-2029
1.4.3 Global Prostaglandin I2 Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Prostaglandin I2 Market Competition by Manufacturers
2.1 Global Prostaglandin I2 Sales Market Share by Manufacturers (2018-2023)
2.2 Global Prostaglandin I2 Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Prostaglandin I2 Average Price by Manufacturers (2018-2023)
2.4 Global Prostaglandin I2 Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Prostaglandin I2, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prostaglandin I2, Product Type & Application
2.7 Prostaglandin I2 Market Competitive Situation and Trends
2.7.1 Prostaglandin I2 Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Prostaglandin I2 Players Market Share by Revenue
2.7.3 Global Prostaglandin I2 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Prostaglandin I2 Retrospective Market Scenario by Region
3.1 Global Prostaglandin I2 Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Prostaglandin I2 Global Prostaglandin I2 Sales by Region: 2018-2029
3.2.1 Global Prostaglandin I2 Sales by Region: 2018-2023
3.2.2 Global Prostaglandin I2 Sales by Region: 2024-2029
3.3 Global Prostaglandin I2 Global Prostaglandin I2 Revenue by Region: 2018-2029
3.3.1 Global Prostaglandin I2 Revenue by Region: 2018-2023
3.3.2 Global Prostaglandin I2 Revenue by Region: 2024-2029
3.4 North America Prostaglandin I2 Market Facts & Figures by Country
3.4.1 North America Prostaglandin I2 Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Prostaglandin I2 Sales by Country (2018-2029)
3.4.3 North America Prostaglandin I2 Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Prostaglandin I2 Market Facts & Figures by Country
3.5.1 Europe Prostaglandin I2 Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Prostaglandin I2 Sales by Country (2018-2029)
3.5.3 Europe Prostaglandin I2 Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prostaglandin I2 Market Facts & Figures by Country
3.6.1 Asia Pacific Prostaglandin I2 Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Prostaglandin I2 Sales by Country (2018-2029)
3.6.3 Asia Pacific Prostaglandin I2 Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Prostaglandin I2 Market Facts & Figures by Country
3.7.1 Latin America Prostaglandin I2 Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Prostaglandin I2 Sales by Country (2018-2029)
3.7.3 Latin America Prostaglandin I2 Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prostaglandin I2 Market Facts & Figures by Country
3.8.1 Middle East and Africa Prostaglandin I2 Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Prostaglandin I2 Sales by Country (2018-2029)
3.8.3 Middle East and Africa Prostaglandin I2 Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Prostaglandin I2 Sales by Type (2018-2029)
4.1.1 Global Prostaglandin I2 Sales by Type (2018-2023)
4.1.2 Global Prostaglandin I2 Sales by Type (2024-2029)
4.1.3 Global Prostaglandin I2 Sales Market Share by Type (2018-2029)
4.2 Global Prostaglandin I2 Revenue by Type (2018-2029)
4.2.1 Global Prostaglandin I2 Revenue by Type (2018-2023)
4.2.2 Global Prostaglandin I2 Revenue by Type (2024-2029)
4.2.3 Global Prostaglandin I2 Revenue Market Share by Type (2018-2029)
4.3 Global Prostaglandin I2 Price by Type (2018-2029)
5 Segment by Application
5.1 Global Prostaglandin I2 Sales by Application (2018-2029)
5.1.1 Global Prostaglandin I2 Sales by Application (2018-2023)
5.1.2 Global Prostaglandin I2 Sales by Application (2024-2029)
5.1.3 Global Prostaglandin I2 Sales Market Share by Application (2018-2029)
5.2 Global Prostaglandin I2 Revenue by Application (2018-2029)
5.2.1 Global Prostaglandin I2 Revenue by Application (2018-2023)
5.2.2 Global Prostaglandin I2 Revenue by Application (2024-2029)
5.2.3 Global Prostaglandin I2 Revenue Market Share by Application (2018-2029)
5.3 Global Prostaglandin I2 Price by Application (2018-2029)
6 Key Companies Profiled
6.1 United Therapeutics
6.1.1 United Therapeutics Corporation Information
6.1.2 United Therapeutics Description and Business Overview
6.1.3 United Therapeutics Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.1.4 United Therapeutics Prostaglandin I2 Product Portfolio
6.1.5 United Therapeutics Recent Developments/Updates
6.2 J & J
6.2.1 J & J Corporation Information
6.2.2 J & J Description and Business Overview
6.2.3 J & J Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.2.4 J & J Prostaglandin I2 Product Portfolio
6.2.5 J & J Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GSK Prostaglandin I2 Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Teva
6.4.1 Teva Corporation Information
6.4.2 Teva Description and Business Overview
6.4.3 Teva Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Teva Prostaglandin I2 Product Portfolio
6.4.5 Teva Recent Developments/Updates
6.5 Toray
6.5.1 Toray Corporation Information
6.5.2 Toray Description and Business Overview
6.5.3 Toray Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Toray Prostaglandin I2 Product Portfolio
6.5.5 Toray Recent Developments/Updates
6.6 Tide Pharma
6.6.1 Tide Pharma Corporation Information
6.6.2 Tide Pharma Description and Business Overview
6.6.3 Tide Pharma Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Tide Pharma Prostaglandin I2 Product Portfolio
6.6.5 Tide Pharma Recent Developments/Updates
6.7 Bayer AG
6.6.1 Bayer AG Corporation Information
6.6.2 Bayer AG Description and Business Overview
6.6.3 Bayer AG Prostaglandin I2 Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer AG Prostaglandin I2 Product Portfolio
6.7.5 Bayer AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prostaglandin I2 Industry Chain Analysis
7.2 Prostaglandin I2 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prostaglandin I2 Production Mode & Process
7.4 Prostaglandin I2 Sales and Marketing
7.4.1 Prostaglandin I2 Sales Channels
7.4.2 Prostaglandin I2 Distributors
7.5 Prostaglandin I2 Customers
8 Prostaglandin I2 Market Dynamics
8.1 Prostaglandin I2 Industry Trends
8.2 Prostaglandin I2 Market Drivers
8.3 Prostaglandin I2 Market Challenges
8.4 Prostaglandin I2 Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
